Published in final edited form as:

Bioorg Med Chem Lett. 2010 January 1; 20(1): 201. doi:10.1016/j.bmcl.2009.10.135.

Discovery of dipiperidines as new antitubercular agents

Elena Bogatcheva^{a,*}, Colleen Hanrahan^{a,b}, Ping Chen^{a,c}, Jacqueline Gearhart^{a,d}, Katherine Sacksteder^a, Leo Einck^a, Carol Nacy^a, and Marina Protopopova^a

^aSequella, Inc., 9610 Medical center Drive, Suite 200, Rockville, MD 20850, USA

Although drugs for treatment of tuberculosis have been available for nearly 50 years, TB remains a global health crisis, killing nearly 2 million people each year. The increasing prevalence of HIV infection and the growing problem of multi-drug resistant TB (MDR-TB) both emphasize the need for new drugs to more effectively treat the disease in all patients.
1-3

We previously reported the synthesis of several combinatorial libraries using solid-phase and solution-phase synthetic techniques.⁴⁻⁵ The first library of asymmetrical ethylenediamines was prepared in an attempt to improve the potency of the existing first line anti-TB drug Ethambutol (EMB),⁴ which was discovered by Lederle Laboratories from a library of 2000 mostly symmetrical diamines.⁶ An evaluation of the structure-activity relationship (SAR) of that original library demonstrated that alterations of the ethylene bridging linker, such as lengthening of the ethylene unit or incorporation of a variety of heteroatoms into the chain, led to a loss of activity. Taking these data into consideration, we generated a library of 63,238 ethylenediamines that was prepared with an emphasis on the introduction of a wide variety of substituents at the two nitrogen atoms of EMB. This led to the identification of the anti-tubercular candidate SQ109,⁷⁻¹¹ which is currently completing Phase I human safety studies. After evaluation of the SAR from our ethylenediamine library, we expanded our compound library by investigating alternative diamine linkers. We prepared a second combinatorial library of diamines using amino alcohol pre-loaded resins with amino acids as building blocks. Amino alcohols attached to the resin were convenient starting synthons, as they provided a protected hydroxyl group and an amino group available for modification. Use of amino acids in the synthesis allowed us to introduce diverse elements into the bridging linker between the two amine components, as well as chirality. This synthetic strategy also allowed us to improve hydrophilicity, a characteristic that was lacking in our original ethylenediamine library. The second amino component was diversified by alkylation or acylation after introduction of the amino acids.

In this paper, we report the solid-phase synthesis of a library of 10,358 diamines based on the general synthetic scheme shown in Figure 1. *In vitro* screening of the library against *M.*

© 2009 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1 301-762-7776; fax: 301-762-7778; elenabogatcheva@sequella.com

^bPresent address: John Hopkins School of Medicine & John Hopkins School of Public Health, Baltimore, MD, USA

^cPresent address: National Institute of Health (NIH), NIAID, 6610 Rockledge Dr., Bethesda MD, USA

^dPresent address: Aeras Global TB Vaccine Foundation, 1405 Research Blvd., Rockville, MD 20850, USA

Supplementary material Available: Complete list of amino acid and their abbreviation, list of carbonyl compounds used in the library synthesis, ¹H NMR and MS spectra for hit compounds, detailed experimental procedures.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

tuberculosis and an evaluation of SAR identified a series of compounds structurally unrelated to existing antitubercular drugs.

Library synthesis began with the coupling of the resin-anchored amino alcohols with Fmoc-protected amino acids. This step was performed on a Quest Synthesizer, allowing 20 reactions to occur in parallel. If the starting amino alcohol was protected with Fmoc (for instance, N-Fmoc-hydroxylamine or N-Fmoc-4-hydroxypiperidine), the protective group was removed using 20% piperidine in DMF prior to coupling (**step a**, Figure 1). We chose ten commercially available amino alcohols (Novabiochem; now EMD Biosciences) for the library preparation (Figure 2, A). Amino acids used as a linker in the synthesis were selected (1) to allow the introduction of various substituents at the bridging ethylenic linker, such as alkyl (Leu, Ile), cycloalkyl (Cha), benzyl (Phe), and heterocycles (His, Trp); (2) to introduce a cyclic moiety between the two nitrogen atoms (Amc), and (3) to incorporate a nitrogen atom into the heterocycle (Inp). Chemical structures of the amino acids that were used in the compounds synthesis are shown in Figure 2, B. Amino acid names and their standard abbreviations are available as Supplementary Material.

After completion of the coupling step (**step b** in Figure 1), we confirmed the formation of intermediate amide for every amino alcohol used. This was necessary because some of the pre-loaded amino alcohols were isomers (3-aminopropan-1-ol and N-methyl-2-aminoethanol, N-Fmoc-4-hydroxypiperidine and prolinol, and 2-aminobutanol and 4-aminobutanol) that could not be distinguished by mass spectrometry (MS) after pooling of the intermediates into the mixtures for further modification and screening. To confirm the synthesis, we cleaved a small amount of each intermediate amide from the resin and analyzed it by positive ion electrospray MS. With the exception of amino acid Arg, all the amino alcohols successfully produced intermediate amides with amino acids.

The synthesized intermediates were pooled into groups of 10, leaving ~50 mg of each resin available for deconvolution. Deconvolution was performed if a group was found to have antibacterial activity. These pools of 10 compounds were evenly distributed into 96-well plates. After Fmoc removal (**step c**, Figure 1), the second amino group was derivatized by acylation with a carboxylic acid, or by reductive alkylation with aldehydes or ketones in the presence of cyanoborohydride (**step d**, Figure 1). The selection of alkylating/acylating reagents (12 carboxylic acids, 20 ketones, and 64 aldehydes) was made both to guarantee structural diversity and ensure that the final diamine products would carry the same or similar types of substituents that had been observed in the hit compounds identified from previous diamine libraries.^{4,5} The carbonyls were organized in a 96-well master plate as 1 M solutions of individual compounds per well and were added to each individual pool of 10 resins, one carbonyl compound per well. Representatives of carbonyls are shown in Figure 2, C; a complete list of the carbonyl compounds used is available as Supplementary Material.

In **step d**, Figure 1, we observed that partial double alkylation occurred on amino acids bearing a primary amino groups (leucine [Leu], isoleucine [Ile], β -cyclohexylalanine [Cha], or 4-aminomethylcyclohexane carboxylic acid [Amc]) when aldehydes were used as alkylating reagents. The ratio of mono to double alkylated compounds did not exceed 5:1. For the amino acids that have a secondary amino group (isonipecotic acid [Inp], proline [Pro], and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [Tic]), overalkylation did not occur. When ketones or carboxylic acids were used in this step, only mono derivatives were formed.

In the next step (**step e**, Figure 1), the intermediate amides were reduced using Red-Al solution in THF. This step proceeded to completion with tertiary amides, while with secondary amides the ratio of reduced to unreduced products varied between 1:1 and 1:10.

Finally, the resulting compounds were cleaved from the resin with 10% of TFA in DCM (**step f**, Figure 1). Formation of the products was monitored by positive electrospray mass spectrometry using 2 randomly selected rows, which allowed us to analyze 25% of the entire library. From this analysis, we calculated a library yield of 63%, suggesting that 10,358 of the targeted 16,320 compounds were formed.

Compound mixtures containing 10+ compounds per well were moved into primary screening without additional purification. After identification, active mixtures were deconvoluted and single compounds from the active group were screened for activity against *M. tuberculosis* using a whole cell assay (see below). The components of the active wells, including side products such as unreduced and double alkylated diamines, were separated by chromatography and screened again to identify the active compound(s).

The 10,358 compound library was tested *in vitro* against the laboratory strain of *M. tuberculosis* (H37Rv) in two screens: 1) direct determination of minimal inhibitory concentration (MIC) using viable organisms in a broth microdilution assay, and 2) a whole cell high-throughput bioluminescence based assay (Luc) with a recombinant *M. tuberculosis* strain that produces light in response to the inhibition of cell wall biosynthesis.^{4,5} Compounds active in both tests were of particular interest to us, since this suggests that inhibition of bacterial growth is likely due to disruption of cell wall biosynthesis, rather than a more generalized toxicity.

Compounds were screened in pools, as prepared, in a dose response, with concentrations ranging from 50 μ M to 0.39 μ M. In this initial screen, we assumed that compounds were synthesized with 100% yield. EMB was used as a positive control in the Luc assay, and both isoniazid (INH) and EMB were used as positive controls in the broth microdilution assay. Wells were considered active if (1) the MIC was equal to or less than 12.5 μ M, or (2) if the MIC was equal to or less than 50 μ M and the response in the Luc assay was at least 1.5x over the background luminescence of the untreated control. Based on these criteria, 198 mixtures were found to be active. Active mixtures were then deconvoluted in a 96-well plate format by resynthesis of the individual diamine components of each active mixture, followed by the screening of the deconvoluted plates in the same assays. Screening results revealed 118 individual compounds with an MIC equal to or lower than 50 μ M, out of which 109 compounds had an MIC equal to or less than 12.5 μ M.

Evaluation of SAR showed that 80 of the 118 hits were derived from two amino alcohols-prolinol (45 hits) and its structural isomer 4-hydroxypiperidine (35 hits). Five amino acids produced the vast majority of the hits (Figure 3); these were Amc, Ile, phenylalanine [Phe], thienylalanine [Thi], and Inp. The carbonyl compounds that contributed most to activity of the final products were 3-(4-chlorophenoxy)-benzaldehyde (c-32, 23 hits), 5-(4-chlorophenyl) furfural (c-33, 12 hits), geranylacetone (c-104, 10 hits), benzyloxyacetaldehyde (c-27, 10 hits), and benzoxybenzaldehyde (c-26, 10 hits). These data correlate well with our previous findings^{4,5}, suggesting that these fragments might be important features for antitubercular activity.

Only 38 of the 118 hits showed a positive response in the Luc assay, suggesting that the target of the majority of compounds was independent of the cell wall synthetic pathway. Certain amino acids were more likely to produce compounds with a positive Luc response, as shown in Figure 3. Interestingly, 9 hits in the Inp series were active in both assays, exhibiting MIC between 3.13 – 25 μ M. The luminescence level in the Luc assay of these hits was between 59%–125% of the response of the assay for the EMB, a cell-wall active drug, implying that the compounds are likely interfering with cell wall biosynthesis. In contrast, the activity of Amc hits in the Luc assay was only about 6% of the EMB control response, while the MIC for

this series fell in the range of 3.13 – 12.5 μm . Compounds from other series that were considered active from the microdilution assay also showed poor activity in the Luc assay. Therefore, we chose to perform further evaluations on hits from the Inp series because of the apparent cell wall activity.

The 9 compounds from the Inp series were prepared on a 150–200 mg scale with at least 95% purity to confirm the MIC and for more in-depth *in vitro* screening. Purity evaluation was performed by GC and/or HPLC. The structures of synthesized compounds were characterized by mass spectroscopy and ^1H NMR. MS and ^1H NMR spectra are available as Supplementary Material.

The MIC of 7 of the 9 purified compounds were between 7.8 – 31.25 μM , as determined by the microdilution method described previously (Table 1); the remaining two compounds did not have activity. The MIC of the most active compounds (SQ609, SQ614, and SQ615) were confirmed using growth in BACTEC medium. The hits were then tested for activity against mammalian cells (HepG2) using an assay that measures *in vitro* metabolism of tetrazonium salts (MTS) to determine IC_{50} (concentration of compound at which 50% of cells remain viable). The selectivity index (SI) is calculated as the ratio of IC_{50} to the MIC, and is designed to estimate a range of drug concentration for *in vivo* studies. Based on the SI, SQ609, SQ614, and SQ615 were the most potent hits for further evaluation. LogP values, also known as the octanol-water partition coefficient, were calculated using ACD software. LogP is used as an indicator of compound lipophilicity and solubility to predict transport properties across cell membranes. For all compounds of the series, LogP values were less than 4, suggesting good absorption. *In vitro* screening data obtained for the Inp hit series is presented in Table 1.

In conclusion, a diverse library of diamine compounds was prepared on solid support and screened *in vitro* against *M. tuberculosis* in two assays. Several compound series were identified. The dipiperidine series was the most promising, since hits of the series were active in both assays, exhibited low mammalian cell toxicity, and had favorable LogP values. Although compounds of this series demonstrated similar MIC to EMB as well as activity in bioluminescence assay, they are structurally different than the ethylenediamine class of compounds, and may have improved properties. The more rigid structure of dipiperidines is likely to reduce the propensity of the compounds to form stable chelates with divalent metal ions, a quality which is associated with the ocular toxicity of ethambutol. In addition, they may have a different mechanism of action from ethambutol, as well as modified pharmacokinetics. This new class of compounds is now being tested in more extensive *in vitro* studies and in mouse models to determine efficacy against *M. tuberculosis in vivo*. These data will allow us to more fully explore their potential as anti-tubercular drugs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the Challenge Grant (UC1A149514) of the National Institute of Allergic and Infectious Diseases (NIAID) of the NIH. The Inter-Institute Program of the NIAID for the Development of AIDS-Related Therapeutics provided MS support for the project. We would like to thank Dr. Carl Hammer at the mass-spec facilities at the NIAID, Mr. Michael Gardner of the Research Triangle Institute International for mass spectra data and Dr. Yiu-fai Lam of the University of Maryland, College Park, for acquiring NMR spectra.

References and notes

1. World Health Organization. Tuberculosis facts. 2009.
http://www.who.int/tb/publications/2009/tbfactsheet_2009_one_page.pdf

2. Rivers EC, Mancera RL. Drug Discovery Today 2008;13:1090. [PubMed: 18840542]
3. Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy C. Medicinal Chemistry 2007;3:301. [PubMed: 17504204]
4. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE III. J. Comb. Chem 2003;5:172. [PubMed: 12625709]
5. Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart G, Barbosa F, Einck L, Nacy C, Protopopova M. J. Med. Chem 2006;49:3045. [PubMed: 16722620]
6. Shepherd RG, Baughn C, Cantral ML, Goodstein B, Thomas JP, Wilkinson RG. Ann. N. Y. Acad. Sci 1966;135:686. [PubMed: 5220237]
7. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart G, Einck L, Nacy C. J. Antimicrob. Chemother 2005;56:968. [PubMed: 16172107]
8. Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M. Journal of Pharmaceutical and Biomedical Analysis 2005;37:793. [PubMed: 15797803]
9. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. Br. J. Pharmacol 2005;144:80. [PubMed: 15644871]
10. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE. Br. J. Pharmacol 2006;145:1.
11. Nikonenko B, Protopopova M, Samala R, Einck L, Nacy C. Antimicrob. Agents Chemother 2007;51:1563. [PubMed: 17242141]

Figure 1.

General synthetic approach for the library preparation. Reagents and conditions: (a) piperidine/DMF (20%, v/v), 20 min, RT; (b) Fmoc protected amino acid (2.5 equiv), HATU (2 equiv.), DIEA (10 equiv.), DMF/CH₂Cl₂ (1/1, v/v), RT, 18 h; (c) piperidine/DMF (20%, v/v), 20 min, RT; (d) carboxylic acid (2.5 equiv), PyBrop (2 equiv.), DIEA (10 equiv.), DMF/CH₂Cl₂ (1/1), RT, 18 h or an aldehyde or ketone (5 equiv.), 1M solution of NaBH₃CN in THF, THF, RT, 18 h; (e) Red-Al (65+ w% in toluene)/THF anhydrous (1/6, v/v), RT, 6 h; (f) 10% TFA/CH₂Cl₂, RT, 20 min.

Figure 2. Reagents used in the library preparation: **A** - amino alcohol pre-loaded resins; **B** - amino acids (amino acids used were of the L configuration (if applicable)); **C**- representatives of the acylating/alkylating reagents.

- - compounds with MIC ≤ 50 μM and activity in Luc assay exceeding 1.5 fold over background luminescence
- - compounds with MIC ≤ 12.5 μM

Figure 3.
Occurrence of amino acids in library hits.

In vitro screening data for Inp series

Table 1

Compound	MIC, μM^a microdilution	MIC, μM^b BACTEC	Luc, % to EMB ^c	IC ₅₀ , μM^d	SI ^e	LogP ^f
SQ609	6.25	15.6	59	56	8.96	3.76
SQ611	31.25	-	102	25	0.80	3.24
SQ612	31.25	-	107	91	2.91	2.37
SQ613	31.25	-	108	41	1.31	3.95
SQ614	7.8	15.65	90	162	20.77	1.91
SQ615	7.8	16	125	30	3.85	3.16
SQ616	15.63	-	70	39	2.50	2.85

^a MIC of the controls in the broth microdilution assay: INH 0.063 $\mu\text{g}/\text{ml}$ (0.46 μM); Rif 0.03 $\mu\text{g}/\text{ml}$ (0.03 μM)

^b MIC of the controls in the BACTEC assay: INH 0.05 $\mu\text{g}/\text{ml}$ (0.36 μM); EMB 1.95 $\mu\text{g}/\text{ml}$ (7.04 μM).

^c percent of luminescence level of tested compounds as compared to the level of EMB (control)

^d determined with HepG2 cells (human hepatocellular liver carcinoma cell line) in MTS assay.

ρ Selectivity index $SI=IC_{50}/MIC$

f LogP, octanol/water partitioning coefficient, was calculated using ACD software.